Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 1;21(1):536.
doi: 10.1186/s12913-021-06566-2.

Costs and healthcare utilisation of patients with chronic kidney disease in Spain

Carlos Escobar  1 , Beatriz Palacios  2 , Unai Aranda  2 , Margarita Capel  2 , Antoni Sicras  3 , Aram Sicras  3 , Antonio Hormigo  4 , Roberto Alcázar  5 , Nicolás Manito  6 , Manuel Botana  7
Affiliations

Costs and healthcare utilisation of patients with chronic kidney disease in Spain

Carlos Escobar et al. BMC Health Serv Res. .

Abstract

Background: Data about the impact of chronic kidney disease (CKD) on health care costs in Spain are scarce This study was aimed to evaluate cumulative costs and healthcare utilisation in CKD in Spain.

Methods: Observational, retrospective, population-based study, which included adults who received care for CKD between 2015 and 2019. Healthcare and medication costs were summarized on a yearly basis starting from the index date (1st January 2015), and then cumulatively until 2019.

Results: We identified 44,214 patients with CKD (year 2015: age 76.4 ± 14.3 years, 49.0% women, albumin-to-creatinine ratio 362.9 ± 176.8 mg/g, estimated glomerular filtration rate 48.7 ± 13.2 mL/min/1.73 m2). During the 2015-2019 period, cumulative CKD associated costs reached 14,728.4 Euros, being cardiovascular disease hospitalizations, particularly due to heart failure and CKD, responsible for 77.1% of costs. Total medication cost accounted for 6.6% of the total cost. There was a progressive decrease in cardiovascular disease hospital costs per year (from 2741.1 Euros in 2015 to 1.971.7 Euros in 2019). This also occurred with cardiovascular and diabetic medication costs, as well as with the proportion of hospitalizations and mortality. Costs and healthcare resources use were higher in the DAPA-CKD like population, but also decreased over time.

Conclusions: Between 2015 and 2019, costs of patients with CKD in Spain were high, with cardiovascular hospitalizations as the key determinant. Medication costs were responsible for only a small proportion of total CKD costs. Improving CKD management, particularly with the use of cardiovascular and renal protective medications may be helpful to reduce CKD burden.

Keywords: Chronic kidney disease; Cost; DAPA-CKD; Healthcare; Hospitalization; Medication.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
Flowchart costs population (2015). CKD: chronic kidney disease
Fig. 2
Fig. 2
Patient cumulative hospital (A), medication (B) and procedures (C) mean costs*. *In Euros. CVD: cardiovascular disease; HF: heart failure; CKD: chronic kidney disease; MI: myocardial infarction; PAD: peripheral artery disease. Cardiorenal costs include HF and CKD costs
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. GBD Chronic Kidney Disease Collaboration Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of Disease study 2017. Lancet. 2020;395:709–733. doi: 10.1016/S0140-6736(20)30045-3. - DOI - PMC - PubMed
    1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–1252. doi: 10.1016/S0140-6736(16)32064-5. - DOI - PubMed
    1. Abubakar II, Tillmann T, Banerjee A. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the global burden of Disease study 2013. Lancet. 2014;385:117–171. - PMC - PubMed
    1. Brück K, Stel VS, Gambaro G, Hallan S, Völzke H, Ärnlöv J. Et al; European CKD burden consortium. CKD prevalence varies across the European general population. J Am Soc Nephrol. 2016;27(7):2135–2147. doi: 10.1681/ASN.2015050542. - DOI - PMC - PubMed
    1. Darlington O, Dickerson C, Evans M, McEwan P, Sörstadius E, Sugrue D, van Haalen H, Garcia Sanchez JJ. Costs and healthcare resource use associated with risk of cardiovascular morbidity in patients with chronic kidney Disease: evidence from a systematic literature review. Adv Ther. 2021;38(2):994–1010. doi: 10.1007/s12325-020-01607-4. - DOI - PMC - PubMed